The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors. The first patient with small cell lung cancer ...

Imdelltra (tarlatamab-dlle) has shown statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared ...

The drug has been specifically authorised to treat patients with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).